-
公开(公告)号：US11999765B2
公开(公告)日：2024-06-04
申请号：US18334189
申请日：2023-06-13
Applicant: SAGE THERAPEUTICS, INC.
CPC classification number: C07J43/003 , C07J41/0044 , C07J41/0094
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
公开(公告)号：US20240101592A1
公开(公告)日：2024-03-28
申请号：US18254209
申请日：2021-11-22
Applicant: Sage Therapeutics, Inc.
Inventor： Maria Jesus Blanco-Pillado
CPC classification number: C07J63/008 , C07J53/008 , C07J43/003
Abstract: Provided herein is a compound of Formula (I)
or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of using the compound of Formula (I) in the treatment of CNS-related disorders.-
公开(公告)号：US20240076310A1
公开(公告)日：2024-03-07
申请号：US18482079
申请日：2023-10-06
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
CPC classification number: C07J43/003 , A61P25/08 , A61P25/14 , A61P25/18 , A61P25/20 , A61P25/24 , C07J7/0085 , C07J31/006
Abstract: Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
-
公开(公告)号：US11912737B2
公开(公告)日：2024-02-27
申请号：US17067093
申请日：2020-10-09
Applicant: Sage Therapeutics, Inc.
Inventor： Gabriel Martinez Botella , Boyd L. Harrison , Albert Jean Robichaud , Francesco G. Salituro , Richard Thomas Beresis
CPC classification number: C07J43/003 , C07J1/007 , C07J1/0059 , C07J1/0074 , C07J7/002 , C07J7/007 , C07J7/0085 , C07J13/007 , C07J21/00 , C07J31/006 , C07J71/001
Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I):
and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.-
公开(公告)号：US20230416300A1
公开(公告)日：2023-12-28
申请号：US18042103
申请日：2021-08-20
Applicant: INTRA-CELLULAR THERAPIES, INC.
Inventor： Peng LI , Robert E. DAVIS , Yupu QIAO
IPC: C07J43/00
CPC classification number: C07J43/003 , C07B2200/05
Abstract: The invention relates to particular substituted (3α,5β-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use as sedatives, hypnotics, anxiolytics, and/or anesthetics, and methods for treatment of depression, anxiety, insomnia, epilepsy, and other central nervous system disorders, as well as to combinations with other agents.
-
Patent Agency Ranking
公开(公告)号：US20230399357A1
公开(公告)日：2023-12-14
申请号：US18455324
申请日：2023-08-24
Applicant: Sage Therapeutics, Inc.
Inventor： Paul Steven Watson , Bret Berner , John Gregory Reid , Jian Wang , James J. Doherty , Stephen Jay Kanes
CPC classification number: C07J43/003 , C07D231/14 , A61P37/00 , A61P25/22 , A61P25/18 , A61P25/24 , A61P25/00 , A61P25/08 , C07B2200/13
Abstract: This invention relates to a crystalline 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I),
and compositions thereof. Also disclosed herein are methods of making the same and methods of using the same.-
![5ALPHA-HYDROXY-6BETA-[2-(1-H-IMIDAZOL-4-YL)-ETHYLAMINO]-CHOLESTAN-3BETA-OL ANALOGUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME FOR USE IN THE TREATMENT OF CANCER](/abs-image/US/2023/12/07/US20230391817A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230391817A1
公开(公告)日：2023-12-07
申请号：US18034317
申请日：2021-10-28
Applicant: DENDROGENIX
Inventor： Stéphane SILVENTE , Quentin MARLIER , Arnaud RIVES , Nicolas CARON , Dario MOSCA , Hélène MICHAUX
CPC classification number: C07J43/003 , A61P35/02 , A61K45/06
Abstract: The invention relates to a novel compound of general formula (I):
and/or a pharmaceutically acceptable salt of such a compound, to a pharmaceutical composition comprising at least said compound, for its use as a medicament for shrinking a mammalian cancerous tumor.-
公开(公告)号：US11807659B2
公开(公告)日：2023-11-07
申请号：US17720938
申请日：2022-04-14
Applicant: INTERCEPT PHARMACEUTICALS, INC.
Inventor： Roberto Pellicciari , Antimo Gioiello , Antonio Macchiarulo , Francoise Perron-Sierra , Klaus Seedorf
CPC classification number: C07J9/005 , A61P1/16 , A61P3/08 , C07J41/00 , C07J41/0061 , C07J43/003
Abstract: The application relates to compounds of formula A:
or a salt, solvate, ester, tautomer, amino acide conjugate, or metabolite thereof. The compounds of formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.-
公开(公告)号：US20230348419A1
公开(公告)日：2023-11-02
申请号：US17761162
申请日：2020-09-18
Applicant: The Regents of the University of California
Inventor： Yuanpei LI , Zhao MA
IPC: C07D401/12 , A61K45/06 , A61K51/12 , C07J43/00 , C07D401/14 , C07D487/22 , B82Y30/00 , B82Y5/00
CPC classification number: C07D401/12 , A61K45/06 , A61K51/1251 , C07J43/003 , C07D401/14 , C07D487/22 , B82Y30/00 , B82Y5/00
Abstract: The present invention provides bisaminoquinoline compounds of Formula (I). The present invention also provides nanocarriers comprising compounds of the present invention, and methods of using the nanocarriers for treating diseases and imaging.
-
公开(公告)号：US20230322847A1
公开(公告)日：2023-10-12
申请号：US18334124
申请日：2023-06-13
Applicant: SAGE THERAPEUTICS, INC.
CPC classification number: C07J43/003 , C07J41/0044 , C07J41/0094
Abstract: Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b) N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
-
-
-
-
-
-
-
-
-
Search Results
1553
records
(took 0.027 seconds)
